Intrathecal methotrexate induces focal cognitive deficits and increases cerebrospinal fluid homocysteine

Yan Li, Veena Vijayanathan, Maria E. Gulinello, Peter D. Cole

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Although most children with acute lymphoblastic leukemia (ALL) can be cured, a significant subset of survivors manifests focal deficits in cognitive function, even when the treatment regimen does not include cranial radiation. Intrathecal administration of the folate antagonist methotrexate (MTX) is necessary to prevent leukemic relapse within the central nervous system, but is suspected to contribute to treatment-induced cognitive dysfunction. To better elucidate the underlying pathophysiology, we sought to establish a rodent model of the cognitive and neurotoxic effects resulting from direct administration of MTX into the cerebrospinal fluid (CSF). MTX or artificial CSF was injected via transcutaneous puncture at the level of the cisterna magna. Subsequent behavioral tests were designed to assess cognitive domains frequently impaired among children treated for ALL. MTX administration produced both recognition and spatial memory deficits, without altering general activity or motor coordination. In addition, MTX significantly reduced folate levels in both CSF and serum and increased CSF homocysteine. Thus, we have established an animal model that mimics the clinical effects of prophylactic intrathecal MTX on cognitive function. Using this model we can further study the pathophysiology of MTX-induced cognitive dysfunction and test protective interventions.

Original languageEnglish (US)
Pages (from-to)428-433
Number of pages6
JournalPharmacology Biochemistry and Behavior
Volume95
Issue number4
DOIs
StatePublished - Jun 2010

Fingerprint

Cerebrospinal fluid
Homocysteine
Methotrexate
Cerebrospinal Fluid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Folic Acid
Cognition
Cisterna Magna
Memory Disorders
Neurology
Set theory
Punctures
Rodentia
Animals
Motor Activity
Central Nervous System
Animal Models
Radiation
Data storage equipment
Recurrence

Keywords

  • Acute lymphoblastic leukemia
  • Cytokines
  • Folate
  • Homocysteine
  • Interleukin-6
  • Intrathecal injection
  • Methotrexate

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Pharmacology
  • Toxicology
  • Behavioral Neuroscience
  • Biological Psychiatry

Cite this

Intrathecal methotrexate induces focal cognitive deficits and increases cerebrospinal fluid homocysteine. / Li, Yan; Vijayanathan, Veena; Gulinello, Maria E.; Cole, Peter D.

In: Pharmacology Biochemistry and Behavior, Vol. 95, No. 4, 06.2010, p. 428-433.

Research output: Contribution to journalArticle

@article{3cb638b379564605afbb0fe3208c05b2,
title = "Intrathecal methotrexate induces focal cognitive deficits and increases cerebrospinal fluid homocysteine",
abstract = "Although most children with acute lymphoblastic leukemia (ALL) can be cured, a significant subset of survivors manifests focal deficits in cognitive function, even when the treatment regimen does not include cranial radiation. Intrathecal administration of the folate antagonist methotrexate (MTX) is necessary to prevent leukemic relapse within the central nervous system, but is suspected to contribute to treatment-induced cognitive dysfunction. To better elucidate the underlying pathophysiology, we sought to establish a rodent model of the cognitive and neurotoxic effects resulting from direct administration of MTX into the cerebrospinal fluid (CSF). MTX or artificial CSF was injected via transcutaneous puncture at the level of the cisterna magna. Subsequent behavioral tests were designed to assess cognitive domains frequently impaired among children treated for ALL. MTX administration produced both recognition and spatial memory deficits, without altering general activity or motor coordination. In addition, MTX significantly reduced folate levels in both CSF and serum and increased CSF homocysteine. Thus, we have established an animal model that mimics the clinical effects of prophylactic intrathecal MTX on cognitive function. Using this model we can further study the pathophysiology of MTX-induced cognitive dysfunction and test protective interventions.",
keywords = "Acute lymphoblastic leukemia, Cytokines, Folate, Homocysteine, Interleukin-6, Intrathecal injection, Methotrexate",
author = "Yan Li and Veena Vijayanathan and Gulinello, {Maria E.} and Cole, {Peter D.}",
year = "2010",
month = "6",
doi = "10.1016/j.pbb.2010.03.003",
language = "English (US)",
volume = "95",
pages = "428--433",
journal = "Pharmacology Biochemistry and Behavior",
issn = "0091-3057",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Intrathecal methotrexate induces focal cognitive deficits and increases cerebrospinal fluid homocysteine

AU - Li, Yan

AU - Vijayanathan, Veena

AU - Gulinello, Maria E.

AU - Cole, Peter D.

PY - 2010/6

Y1 - 2010/6

N2 - Although most children with acute lymphoblastic leukemia (ALL) can be cured, a significant subset of survivors manifests focal deficits in cognitive function, even when the treatment regimen does not include cranial radiation. Intrathecal administration of the folate antagonist methotrexate (MTX) is necessary to prevent leukemic relapse within the central nervous system, but is suspected to contribute to treatment-induced cognitive dysfunction. To better elucidate the underlying pathophysiology, we sought to establish a rodent model of the cognitive and neurotoxic effects resulting from direct administration of MTX into the cerebrospinal fluid (CSF). MTX or artificial CSF was injected via transcutaneous puncture at the level of the cisterna magna. Subsequent behavioral tests were designed to assess cognitive domains frequently impaired among children treated for ALL. MTX administration produced both recognition and spatial memory deficits, without altering general activity or motor coordination. In addition, MTX significantly reduced folate levels in both CSF and serum and increased CSF homocysteine. Thus, we have established an animal model that mimics the clinical effects of prophylactic intrathecal MTX on cognitive function. Using this model we can further study the pathophysiology of MTX-induced cognitive dysfunction and test protective interventions.

AB - Although most children with acute lymphoblastic leukemia (ALL) can be cured, a significant subset of survivors manifests focal deficits in cognitive function, even when the treatment regimen does not include cranial radiation. Intrathecal administration of the folate antagonist methotrexate (MTX) is necessary to prevent leukemic relapse within the central nervous system, but is suspected to contribute to treatment-induced cognitive dysfunction. To better elucidate the underlying pathophysiology, we sought to establish a rodent model of the cognitive and neurotoxic effects resulting from direct administration of MTX into the cerebrospinal fluid (CSF). MTX or artificial CSF was injected via transcutaneous puncture at the level of the cisterna magna. Subsequent behavioral tests were designed to assess cognitive domains frequently impaired among children treated for ALL. MTX administration produced both recognition and spatial memory deficits, without altering general activity or motor coordination. In addition, MTX significantly reduced folate levels in both CSF and serum and increased CSF homocysteine. Thus, we have established an animal model that mimics the clinical effects of prophylactic intrathecal MTX on cognitive function. Using this model we can further study the pathophysiology of MTX-induced cognitive dysfunction and test protective interventions.

KW - Acute lymphoblastic leukemia

KW - Cytokines

KW - Folate

KW - Homocysteine

KW - Interleukin-6

KW - Intrathecal injection

KW - Methotrexate

UR - http://www.scopus.com/inward/record.url?scp=77952544767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952544767&partnerID=8YFLogxK

U2 - 10.1016/j.pbb.2010.03.003

DO - 10.1016/j.pbb.2010.03.003

M3 - Article

C2 - 20332001

AN - SCOPUS:77952544767

VL - 95

SP - 428

EP - 433

JO - Pharmacology Biochemistry and Behavior

JF - Pharmacology Biochemistry and Behavior

SN - 0091-3057

IS - 4

ER -